National Tribune
Saturday, 21 November 2026
Health

[HIV Glasgow 2026] aidsmap | Hepatitis B reactivation after switch to injectable treatment: rare, but proceed with caution

Although hepatitis B reactivation is rare after a switch to injectable cabotegravir/rilpivirine, people with HIV require careful monitoring before and after a switch to assess protection against hepatitis B and reactivation risks, studies presented at HIV Glasgow 2026 suggest.

Cohort studies carried out in Spain and Italy found that rates of hepatitis B reactivation after switching to injectable cabotegravir/rilpivirine were low or non-existent. But the Italian study highlighted the risk of poor or non-existent immunity to hepatitis B despite vaccination. Three vaccinated people acquired hepatitis B during the study, although their infections were asymptomatic and detected only through tests for hepatitis B core antibody (anti-HBc) and surface antibody (anti-HBs).

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.

Originally reported by European AIDS Treatment Group.